Anti-fibrotic effects of pirfenidone and rapamycin in primary IPF fibroblasts and human alveolar epithelial cells

Anti-fibrotic effects of pirfenidone and rapamycin in primary IPF fibroblasts and human alveolar epithelial cells

Abstract Background Pirfenidone, a pleiotropic anti-fibrotic treatment, has been shown to slow down disease progression of idiopathic pulmonary fibrosis (IPF), a fatal and devastating lung disease. Rapamycin, an inhibitor of fibroblast proliferation could be a potential anti-fibrotic drug to improve...

Full description

Bibliographic Details
Main Authors: M. Molina-Molina, C. Machahua-Huamani, V. Vicens-Zygmunt, R. Llatjós, I. Escobar, E. Sala-Llinas, P. Luburich-Hernaiz, J. Dorca, A. Montes-Worboys
Format: Article
Language:English
Published: BMC 2018-04-01
Series:BMC Pulmonary Medicine
Subjects:
Pirfenidone
Rapamycin
Idiopathic pulmonary fibrosis
Pulmonary fibrosis
Cell migration
Extracellular matrix proteins
Online Access:http://link.springer.com/article/10.1186/s12890-018-0626-4

Internet

http://link.springer.com/article/10.1186/s12890-018-0626-4

Similar Items